3. Skyrizi

Skyrizi
Skyrizi's annual maintenance price of $59,000, before rebates and discounts, "is lower than the most widely prescribed biologic treatments for moderate to severe plaque psoriasis,” a spokeswoman said via email after its approval. (AbbVie)

Generic name: risankizumab-rzaa
Company: AbbVie
Disease: psoriasis
2024 sales estimate: $2.1 billion 

How do you break into a market as crowded as the next-generation psoriasis field? Come armed with data that might just be best-in-class. At least, that’s what AbbVie’s Skyrizi did, analysts figure.

RELATED: In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst

The psoriasis newcomer grabbed the FDA’s favor in April, joining Johnson & Johnson’s Tremfya and Sun’s Ilumya in the IL-23 class. And it won that nod on the back of a trove of positive data. Skyrizi “should benefit from … best-in-category efficacy,” SVB Leerink analyst Geoffrey Porges wrote to clients at the time, pointing to “stellar” phase 3 results that showed Skyrizi could clear skin lesions by 90% in up to three-quarters of patients within a week.

AbbVie isn’t just relying on the numbers to get the job done, though. It also boasts a convenience boost over its J&J rival, which requires maintenance doses every eight weeks. After initial Skyrizi doses at the outset and four weeks later, patients on the AbbVie drug only require four doses per year.

RELATED: AbbVie shakes up psoriasis field with blockbuster-to-be newcomer Skyrizi

The Illinois drugmaker is also hoping its pricing strategy will help dent Tremfya’s market share. It put an $88,500 first-year sticker on the drug to reflect the two starter doses, and that list price drops to $59,000 down the line. The annual maintenance price "is lower than the most widely prescribed biologic treatments for moderate to severe plaque psoriasis,” a spokeswoman wrote by email shortly after approval.

The drug also has plenty of prospects beyond psoriasis. It’s currently in phase 3 testing as a treatment for Crohn’s disease, ulcerative colitis and psoriatic arthritis.

Thing is, so are many of its competitors outside the IL-23 world. In addition to Tremfya and Ilumya, Skyrizi is also up against the IL-17s—Novartis’ Cosentyx, Eli Lilly’s Taltz and Valeant’s Siliq—as well as IL-12/23 drug Stelara from J&J, Celgene psoriasis pill Otezla, and the class of anti-TNF giants, led by AbbVie’s Humira.

3. Skyrizi

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?